CCM
KPTI icon

Coldstream Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Coldstream Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-331
Closed -$1.24K – 2290
2025
Q1 		$1.24K Buy
+331
New +$2.83K ﹤0.01% 3124

Other funds holding KPTI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Coldstream Capital Management's KPTI Position: Q2 2025 in Review

Coldstream Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2025, closing a stake of 331 shares — an estimated $1.24K sold.

Coldstream Capital Management first reported a position in KPTI in Q1 2025 and held it in 1 quarter. The position peaked at $1.24K in Q1 2025. 50 funds tracked by Wall St. Rank hold KPTI as of Q2 2025.

  • Coldstream Capital Management reported no remaining Karyopharm Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 331 Karyopharm Therapeutics shares in Q2 2025, an estimated $1.24K.
  • Coldstream Capital Management first reported a position in Karyopharm Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Karyopharm Therapeutics position peaked at $1.24K in Q1 2025.
  • 50 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.